Company intelligence / Profile preview

Medicine Invention Design

Rockville, Maryland, United Statescdek.pharmacy.purdue.edu ↗

Ownership: Private
Development stage: Other

Overview

Medicine Invention Design has developed a prophylactic vaccine candidate targeting COVID-19. Their lead asset is "COVID-19 Spike-GM-CSF Protein Lactated Ringer's Injection," which reached Early Phase 1 clinical trials as of August 2023. No published clinical results are available in the public domain.

Therapeutic areas: Infectious Diseases
Modalities: Prophylactic vaccineProtein
Industry: Biotech

Beyond the preview

Go deeper on Medicine Invention Design.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Medicine Invention Design.

Explore the full profile